A Composition for Predicting Future Onset of Pancreatic Cancer

• Main Authors: MINYOUNG LEE, JOON SEONG PARK, SHINAE KANG, HO SEON PARK
• Format: Patent
• Language: English; Korean
• Published: 04.10.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

The present invention relates to a composition for predicting the occurrence of pancreatic cancer and a composition for diagnosing pancreatic cancer in diabetic patients. By measuring a plasma Wnt5a level, the future risk of developing pancreatic cancer in an undiagnosed subject is predicted with high reliability, which can be usefully used for early establishment of a treatment strategy and improvement of a survival rate of a patient. The present invention can provide important clinical information by being applied as a biomarker for screening causative diseases, which can identify whether currently onset diabetes is a simple metabolic disease or in a hyperglycemic state triggered by pancreatic cancer. 본 발명은 췌장암 발병 예측용 조성물 및 당뇨병 환자에서의 췌장암 진단용 조성물에 관한 것이다. 본 발명은 혈장의 Wnt5a 수준 측정을 통해 췌장암이 임상적으로 발병하지 않은 미확진 대상체의 향후 발병 위험성을 높은 신뢰도로 예측함으로써 치료 전략의 조기 수립 및 환자의 생존율 개선에 유용하게 이용될 수 있다. 본 발명은 또한 현재 발병한 당뇨병이 단순한 대사질환인지 혹은 췌장암에 의해 촉발된 고혈당 상태인지를 식별할 수 있는 원인 질환 선별용 바이오마커로 적용됨으로써 중요한 임상 정보를 제공할 수 있다.